Sustained release ocular drug delivery systems for glaucoma therapy

References

• Pan Y, Varma R. Natural history of glaucoma. Indian J Ophthalmol. 2011;59(Suppl1):S19.
   PubMedGoogle Scholar
• Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmol. 2014;121(11):2081–2090. DOI:10.1016/j.ophtha.2014.05.013
   PubMed Web of Science ®Google Scholar
• Cook C, Foster P. Epidemiology of glaucoma: what’s new? Can J Ophthalmol. 2012;47(3):223–226.
   PubMed Web of Science ®Google Scholar
• Gooch N, Molokhia SA, Condie R, et al. Ocular drug delivery for glaucoma management. Pharmaceutics. 2012;4(1):197–211. DOI:10.3390/pharmaceutics4010197
   PubMedGoogle Scholar
• Lee DA, Higginbotham EJ. Glaucoma and its treatment: a review. Am J Health Syst Pharm. 2005;62(7):691–699.
   PubMed Web of Science ®Google Scholar
• Artero-Castro A, Rodriguez-Jimenez FJ, Jendelova P, et al. Glaucoma as a neurodegenerative disease caused by intrinsic vulnerability factors. Prog Neurobiol. 2020;193:101817.
   PubMed Web of Science ®Google Scholar
• Van de Velde S, De Groef L, Stalmans I, et al. Towards axonal regeneration and neuroprotection in glaucoma: rho kinase inhibitors as promising therapeutics. progress in neurobiology. Prog Neurobiol. 2015;131:105–119.
   PubMed Web of Science ®Google Scholar
• Al-Kinani AA, Calabrese G, Vangala A, et al. Nanotechnology in ophthalmic drug delivery. In: Patenting nanomedicines. Springer; 2012. p. 277–303. DOI:10.1007/978-3-642-29265-1_9
   Google Scholar
• Le Bourlais C, Acar L, Zia H, et al. Ophthalmic drug delivery systems—recent advances. progress in retinal and eye research. Prog Retin Eye Res. 1998;17(1):33–58. DOI:10.1016/S1350-9462(97)00002-5
   PubMed Web of Science ®Google Scholar
• Andres-Guerrero V, Bravo-Osuna I, Pastoriza P, et al. Novel technologies for the delivery of ocular therapeutics in glaucoma. J Drug Delivery Sci Technol. 2017;42:181–192.
   Web of Science ®Google Scholar
• Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014;8:903.
   PubMedGoogle Scholar
• Kalouda P, Keskini C, Anastasopoulos E, et al. Achievements and limits of current medical therapy of glaucoma, in glaucoma surgery. Karger Publishers; 2017. p. 1–14. DOI:10.1159/000458482
   Google Scholar
• Toris CB. Pharmacotherapies for glaucoma. Curr Mol Med. 2010;10(9):824–840.
   PubMed Web of Science ®Google Scholar
• Young CEC, Kahook MY, Seibold LK. Novel drug delivery systems for the treatment of glaucoma. Curr Ophthalmol Rep. 2019;7(2):143–149.
   Google Scholar
• Hennessy AL, Katz J, Covert D, et al. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol. 2011;152(6):982–988. DOI:10.1016/j.ajo.2011.05.015
   PubMed Web of Science ®Google Scholar
• Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144(4):533–540. e2. DOI:10.1016/j.ajo.2007.06.012
   PubMed Web of Science ®Google Scholar
• Walker R, Whittlesea C. Clinical pharmacy and therapeutics E-Book. 5th ed. Churchill Livingstone, Elsevier Health Sciences; 2011. https://iauthor.integra.co.in/editor?docid=DFA83051&isProceed=1
   Google Scholar
• Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmol. 2015;122(7):1308–1316. DOI:10.1016/j.ophtha.2015.03.026
   PubMed Web of Science ®Google Scholar
• Olthoff CM, SCHOUTEN J, VANDEBORNE B, et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review. Ophthalmol. 2005;112(6):953–961. e7. DOI:10.1016/j.ophtha.2004.12.035
   PubMed Web of Science ®Google Scholar
• Kim JH, Caprioli J. Intraocular pressure fluctuation: is it important? J Ophthalmic Vis Res. 2018;13(2):170.
   PubMed Web of Science ®Google Scholar
• Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–142. DOI:10.1097/00061198-200004000-00002
   PubMed Web of Science ®Google Scholar
• Adams CM, Stacy R, Rangaswamy N, et al. Glaucoma-next generation therapeutics: impossible to possible. Pharm Res. 2019;36(2):25. DOI:10.1007/s11095-018-2557-4
   Web of Science ®Google Scholar
• Aref AA. Sustained drug delivery for glaucoma: current data and future trends. Curr Opin Ophthalmol. 2017;28(2):169–174.
   PubMed Web of Science ®Google Scholar
• Kesav NP, Ertel MK, Seibold LK, et al. Sustained-release drug delivery systems for the treatment of glaucoma. Int J Ophthalmol. 2021;14(1):148. DOI:10.18240/ijo.2021.01.21
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Pierscionek B, Carew M, Wu Z, Alany RG. Critical appraisal of alternative irritation models: three decades of testing ophthalmic pharmaceuticals. Br Med Bull. 2015;113(1):59–71. DOI:10.1093/bmb/ldv002
   PubMed Web of Science ®Google Scholar
• Al-Kinani AA, Naughton DP, Calabrese G, et al. Analysis of 2-oxothiazolidine-4-carboxylic acid by hydrophilic interaction liquid chromatography: application for ocular delivery using chitosan nanoparticles. Anal Bioanal Chem. 2015;407(9):2645–2650. DOI:10.1007/s00216-015-8494-8
   PubMed Web of Science ®Google Scholar
• Hoying P, van Beek L. Pharmacological therapy for glaucoma: a review. Drugs. 2000;59:411–434.
   PubMed Web of Science ®Google Scholar
• Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015;31(2):63–77. DOI:10.1089/jop.2014.0067
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. the lancet. Lancet. 2015;385(9975):1295–1304. DOI:10.1016/S0140-6736(14)62111-5
   PubMed Web of Science ®Google Scholar
• Prasanna G, Li B, Mogi M, Rice DS. Pharmacology of novel intraocular pressure-lowering targets that enhance conventional outflow facility: pitfalls, promises and what lies ahead? Eur J Pharmacol. 2016;787:47–56.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AGP, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmol. 2008;115(7):1117–1122. e1. DOI:10.1016/j.ophtha.2007.10.004
   PubMed Web of Science ®Google Scholar
• Drance SM. Diurnal variation of intraocular pressure in treated glaucoma: significance in patients with chronic simple glaucoma. Arch Ophtalmol. 1963;70(3):302–311.
   PubMedGoogle Scholar
• Caprioli J, Coleman AL. Intraocular pressure fluctuation: a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmol. 2008;115(7):1123–1129. e3.
   PubMed Web of Science ®Google Scholar
• Lee SS, Hughes P, Ross AD, et al. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27(10):2043–2053. DOI:10.1007/s11095-010-0159-x
   PubMed Web of Science ®Google Scholar
• Parveen N, Joshi H. Ocuserts: a novel formulation approach in drug delivery system. Saudi J Med Pharm Sci. 2020;06(05):420–425.
   Google Scholar
• Kompella UB, Hartman RR, Patil MA. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog Retin Eye Res. 2020;82:100901.
   PubMed Web of Science ®Google Scholar
• Saettone MF, Salminen L. Ocular inserts for topical delivery. Advanced drug delivery reviews. 1995;16(1):95–106.
   Web of Science ®Google Scholar
• Dunbar GE, Shen BY, Aref AA. The sensimed triggerfish contact lens sensor: efficacy, safety, and patient perspectives. Clin Ophthalmol. 2017;11:875.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Fathalla Z, Seyfoddin A, et al. Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: inserts, patches, wafers, and implants. advanced drug delivery reviews. Adv Drug Delivery Rev. 2021;177:113957.
   PubMed Web of Science ®Google Scholar
• Manickavasagam D, Oyewumi MO. Critical assessment of implantable drug delivery devices in glaucoma management. J Drug Deliv. 2013;2013. DOI:10.1155/2013/895013
   PubMedGoogle Scholar
• Shouchane-Blum K, Geffen N, Zahavi A. Sustained drug delivery platforms–A new era for glaucoma treatment. CLEVER Clin Exp Vis Eye Resh. 2019;2(1):22.
   Google Scholar
• Fedorchak MV, Conner IP, Schuman JS, et al. Long term glaucoma drug delivery using a topically retained gel/microsphere eye drop. Sci Rep. 2017;7(1):1–11. DOI:10.1038/s41598-017-09379-8
   PubMedGoogle Scholar
• Shafiee A Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. Clin Ophthalmol. 2013;7:1549.
   PubMedGoogle Scholar
• Brandt JD, DuBiner HB, Benza R, et al. Long-term safety and efficacy of a sustained-release bimatoprost ocular ring. Ophthalmol. 2017;124(10):1565–1566. DOI:10.1016/j.ophtha.2017.04.022
   PubMed Web of Science ®Google Scholar
• Maulvi FA, Soni TG, Shah DO. A review on therapeutic contact lenses for ocular drug delivery. Drug Delivery. 2016;23(8):3017–3026.
   PubMed Web of Science ®Google Scholar
• Zhang X, Cao X, Qi P. Therapeutic contact lenses for ophthalmic drug delivery: major challenges. J Biomater Sci Polym Ed. 2020;31(4):549–560.
   PubMed Web of Science ®Google Scholar
• Hsu K-H, Carbia BE, Plummer C, Chauhan A. Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy. Eur J Pharm Biopharm. 2015;94:312–321.
   PubMed Web of Science ®Google Scholar
• Ciolino JB, Stefanescu CF, Ross AE, et al. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials. 2014;35(1):432–439. DOI:10.1016/j.biomaterials.2013.09.032
   PubMed Web of Science ®Google Scholar
• Kim H-J, Zhang K, Moore L, Ho D. Diamond nanogel-embedded contact lenses mediate lysozyme-dependent therapeutic release. ACS Nano. 2014;8(3):2998–3005. DOI:10.1021/nn5002968
   PubMed Web of Science ®Google Scholar
• Deng J, Chen S, Chen J, et al. Self-reporting colorimetric analysis of drug release by molecular imprinted structural color contact lens. ACS Appl Mater Interfaces. 2018;10(40):34611–34617. DOI:10.1021/acsami.8b11655
   PubMed Web of Science ®Google Scholar
• Leahy C, Ellis EJ, Ellis JY, et al. Efficacy of a topical ocular drug delivery device (TODDD) for the treatment of glaucoma by telemetric measurement of IOP in the normal rabbit. Invest Ophthalmol Visual Sci. 2007;48(13):5816–5816.
   Google Scholar
• Perera SA, Nongpiur M, Chew P, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an asian population. Clin Ophthalmol. 2016;10:757.
   PubMed Web of Science ®Google Scholar
• Utkhede D, William R. Improving retention rates for sustained therapeutic delivery through punctal plugs. Invest Ophthalmol Visual Sci. 2018;59(9):5675–5675.
   Web of Science ®Google Scholar
• Lewis RA, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am J Ophthalmol. 2017;175:137–147.
   PubMed Web of Science ®Google Scholar
• Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients. 3 May 2020 [cited 2020 Apr 8]; Available from: https://www.allergan.com/News/Details/2020/03/Allergan%20Receives%20FDA%20Approval%20for%20DURYSTA%20bimatoprost%20implant%20the%20First%20and%20Only%20Intracameral%20Biode.
   Google Scholar
• Navratil T, Garcia A, Tully J, et al. Preclinical evaluation of ENV515 (travoprost) intracameral implant-clinical candidate for treatment of glaucoma targeting six-month duration of action. Invest Ophthalmol Visual Sci. 2014;55(13):3548–3548.
   Web of Science ®Google Scholar
• Envisia therapeutics releases interim ENV515 (travoprost XR) phase 2 data demonstrating 11-month duration-of-action after a single dose in patients with glaucoma feb 03, 2017, 07: 45 ET [cited 2020 Apr 10]; Available from: https://www.prnewswire.com/news-releases/envisia-therapeutics-releases-interim-env515-travoprost-xr-phase-2-data-demonstrating-11-month-duration-of-action-after-a-single-dose-in-patients-with-glaucoma-300401812.html.
   Google Scholar
• Trevino L, Navratil T, Robeson R, et al. Intracameral conversion of travoprost to travoprost acid in the normotensive beagle dog model. Invest Ophthalmol Visual Sci. 2014;55(13):5270–5270.
   Web of Science ®Google Scholar
• Ocular Therapeutix OTX-TP trial misses primary endpoint. May 22, 2019 [cited 2020 Apr 21]; Available from: https://www.drugdeliverybusiness.com/ocular-therapeutix-otx-tp-trial-misses-primary-endpoint/.
   Google Scholar
• Glaukos presentation.Published in: Investor Relations. Presented at: 18:31:51 UTC; 2018. [cited 2020 Apr 8]; Available from: https://www.slideshare.net/glaukos/glaukos-january-2018-presentation.
   Google Scholar
• Glaukos Corporation’s iDose™ Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort. Jan 10, 2018 [cited 2020 Apr 8]; Available from: http://investors.glaukos.com/investors/press-releases/press-release-details/2018/Glaukos-Corporations-iDose-Travoprost-Achieves-Sustained-IOP-Reduction-and-Favorable-Safety-Profile-in-12-Month-Interim-Cohort/default.aspx.
   Google Scholar
• Komaromy AM, Koehl K, Harman CD, et al. Long-term intraocular pressure (IOP) control by means of a novel biodegradable intracameral (IC) latanoprost free acid (LFA) implant. Invest Ophthalmol Visual Sci. 2017;58(8):4591–4591.
   Web of Science ®Google Scholar
• Kim J, Kudisch M, da Silva NR, et al. Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent. JControlled Release. 2018;269:45–51.
   PubMed Web of Science ®Google Scholar
• Kim J, Kudisch M, Mudumba S, et al. Biocompatibility and pharmacokinetic analysis of an intracameral polycaprolactone drug delivery implant for glaucoma. Invest Ophthalmol Vis Sci. 2016;57(10):4341–4346. DOI:10.1167/iovs.16-19585
   PubMed Web of Science ®Google Scholar
• pSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device in Ocular Hypertension and Glaucoma. Watertown, Mass. Jun 14, 2011 [cited 2020 Apr 10]; Available from: https://www.pfizer.com/files/partnering/061411_psivida_announces_phase_clinical_study.pdf.
   Google Scholar
• Awwad S, Mohamed Ahmed AH, Sharma G, et al. Principles of pharmacology in the eye. Br J Pharmacol. 2017;174(23):4205–4223. DOI:10.1111/bph.14024
   PubMed Web of Science ®Google Scholar
• Fahmy HM, Saad EA, Sabra NM, et al. Treatment merits of latanoprost/thymoquinone–encapsulated liposome for glaucomatus rabbits. Int J Pharmaceut. 2018;548(1):597–608. DOI:10.1016/j.ijpharm.2018.07.012
   PubMed Web of Science ®Google Scholar
• Krauland AH, Leitner VM, Bernkop‐Schnürch A. Improvement in the in situ gelling properties of deacetylated gellan gum by the immobilization of thiol groups. J Pharmaceut sci. 2003;92(6):1234–1241.
   PubMed Web of Science ®Google Scholar
• Patel A, Cholkar K, Agrahari V, et al. Ocular drug delivery systems: an overview. World J Pharm. 2013;2(2):47. DOI:10.5497/wjp.v2.i2.47
   PubMedGoogle Scholar
• Uusitalo H, Kähönen M, Ropo A, et al. Improved systemic safety and risk–benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefe’s Arch Clin Exp Ophthalmol. 2006;244(11):1491–1496. DOI:10.1007/s00417-006-0328-0
   PubMed Web of Science ®Google Scholar
• Bennett L. Topical versus systemic ocular drug delivery, in ocular drug delivery: advances, challenges and applications. Springer. 2016;p. 53–74. DOI:10.1007/978-3-319-47691-9_5
   Google Scholar
• Abdelkader H, Pierscionek B, Alany RG. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies. Int J Pharmaceut. 2014;477(1–2):631–642.
   PubMed Web of Science ®Google Scholar
• Terreni E, Chetoni P, Burgalassi S, et al. A hybrid ocular delivery system of cyclosporine-A comprising nanomicelle-laden polymeric inserts with improved efficacy and tolerability. Biomater Sci. 2021;9(24):8235–8248. DOI:10.1039/D1BM01453F
   PubMed Web of Science ®Google Scholar
• Al-Kinani AA, Pleyer U. Ophthalmic gels: past, present and future. Adv Drug Delivery Rev. 2018;126:113–126.
   PubMed Web of Science ®Google Scholar
• The Pipeline. Several groups are working to overcome challenges inherent to drop therapy. May, 2018.
   Google Scholar
• Narayanaswamy R, Torchilin VP. Hydrogels and their applications in targeted drug delivery. Molecules. 2019;24(3):603.
   PubMed Web of Science ®Google Scholar
• Fedorchak MV, Conner IP, Medina CA, et al. 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres. Exp Eye Res. 2014;125:210–216.
   PubMed Web of Science ®Google Scholar
• Jain D, et al. Newer trends in in situ gelling systems for controlled ocular drug delivery. J Anal Pharm Res. 2016;2(3):00022. DOI:10.15406/japlr.2016.02.00022
   Google Scholar
• Ding S. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today. 1998;1(8):328–335.
   Google Scholar
• Patel SP, Vaishya R, Pal D, Mitra AK. Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases. J Microencapsul. 2016;33(2):103–113. DOI:10.3109/02652048.2015.1134685
   PubMed Web of Science ®Google Scholar
• Patel SP, Vaishya R, Pal D, et al. Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery. AAPS Pharm Sci Tech. 2015;16(2):327–343. DOI:10.1208/s12249-014-0196-6
   PubMed Web of Science ®Google Scholar
• Remington JP. Remington: the science and practice of pharmacy. Vol. 1. Lippincott Williams & Wilkins; 2006.
   Google Scholar
• De Souza JF, Maia KN, Patrício PS, et al. Ocular inserts based on chitosan and brimonidine tartrate: development, characterization and biocompatibility. J Drug Delivery Sci Technol. 2016;32:21–30.
   Web of Science ®Google Scholar
• Liu C, Lan Q, He W, et al. Octa-arginine modified lipid emulsions as a potential ocular delivery system for disulfiram: a study of the corneal permeation, transcorneal mechanism and anti-cataract effect. Colloids Surf B Biointerfaces. 2017;160:305–314.
   PubMed Web of Science ®Google Scholar
• Osi B, Khoder M, Al-Kinani AA, et al. Pharmaceutical, biomedical and ophthalmic applications of biodegradable polymers (BDPs): literature and patent review. Pharm Dev Technol. 2022;27(3):1–16. DOI:10.1080/10837450.2022.2055063
   PubMed Web of Science ®Google Scholar
• Brandt JD, Sall K, DuBiner H, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmol. 2016;123(8):1685–1694. DOI:10.1016/j.ophtha.2016.04.026
   PubMed Web of Science ®Google Scholar
• Hermann MM, Üstündag C, Diestelhorst M. Electronic compliance monitoring of topical treatment after ophthalmic surgery. Int Ophthalmol. 2010;30(4):385–390.
   PubMedGoogle Scholar
• Rathore K, Nema R. Review on ocular inserts. Int J Pharmtech Res. 2009;1(2):164–169.
   Google Scholar
• Karthikeyan D, Bhowmick M, Pandey V, et al. The concept of ocular inserts as drug delivery systems: an overview. Asian J Pharm (AJP). 2014;2(4):192. DOI:10.4103/0973-8398.45031
   Google Scholar
• Kumari A, Sharma P, Garg V, et al. Ocular inserts—advancement in therapy of eye diseases. J Adv Pharm Tech Res. 2010;1(3):291. DOI:10.4103/0110-5558.72419
   PubMedGoogle Scholar
• A study to evaluate efficacy and safety of a fixed combination ocular insert in participants with open-angle glaucoma or ocular hypertension. [cited 2021 3 March]; Available from: https://clinicaltrials.gov/ct2/show/results/NCT02742649?view=results.
   Google Scholar
• Goldberg I, Gil Pina R, Lanzagorta-Aresti A, et al. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. Br J Ophthalmol. 2014;98(7):926–931. DOI:10.1136/bjophthalmol-2013-304064
   PubMed Web of Science ®Google Scholar
• Peppas N, Kumar N, Kumar MR. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50(1):27–46. DOI:10.1016/S0939-6411(00)00090-4
   PubMed Web of Science ®Google Scholar
• Mehta P, Al-Kinani AA, Qutachi O, et al. Assessing the ex vivo permeation behaviour of functionalised contact lens coatings engineered using an electrohydrodynamic technique. J Phys Mater. 2018;2(1):014002. DOI:10.1088/2515-7639/aaf263
   Google Scholar
• Mosuela R, Thapa A, Alany RG, et al. Contact lenses: clinical evaluation, associated challenges and perspectives. Pharm Pharmacol Int J. 2017;5(3):00119. DOI:10.15406/ppij.2017.05.00119
   Google Scholar
• Singh RB, Ichhpujani P, Thakur S, et al. Promising therapeutic drug delivery systems for glaucoma: a comprehensive review. Ophthalmol Eye Dis. 2020;12:2515841420905740.
   Google Scholar
• Musgrave CSA, Fang F. Contact lens materials: a materials science perspective. Materials. 2019;12(2):261.
   PubMed Web of Science ®Google Scholar
• ElShaer A, Mustafa S, Kasar M, et al. Nanoparticle-laden contact lens for controlled ocular delivery of prednisolone: formulation optimization using statistical experimental design. Pharmaceutics. 2016;8(2):14. DOI:10.3390/pharmaceutics8020014
   PubMed Web of Science ®Google Scholar
• Carvalho I, Marques CS, Oliveira RS, et al. Sustained drug release by contact lenses for glaucoma treatment—a review. JControlled Release. 2015;202:76–82.
   PubMed Web of Science ®Google Scholar
• Guzman-Aranguez A, Colligris B, Pintor J. Contact lenses: promising devices for ocular drug delivery. J Ocul Pharmacol Ther. 2013;29(2):189–199.
   PubMed Web of Science ®Google Scholar
• Mehta P, Al-Kinani AA, Arshad MS, et al. Engineering and development of chitosan-based nanocoatings for ocular contact lenses. J Pharmaceut sci. 2019;108(4):1540–1551. DOI:10.1016/j.xphs.2018.11.036
   PubMed Web of Science ®Google Scholar
• Mehta P, Al-Kinani AA, Haj-Ahmad R, et al. Electrically atomised formulations of timolol maleate for direct and on-demand ocular lens coatings. Eur J Pharm Biopharm. 2017;119:170–184.
   PubMed Web of Science ®Google Scholar
• ElShaer A, Ghatora B, Mustafa S, et al. Contact lenses as drug reservoirs & delivery systems: the successes & challenges. Ther Deliv. 2014;5(10):1085–1100. DOI:10.4155/tde.14.73
   PubMedGoogle Scholar
• Mati Therapeutics Inc. Announces initiation of phase II study to compare latanoprost punctal plug delivery system (L-PPDS) to timolol eye drops. Oct. 28, 2013 [cited Jul, 11, 2020; Available from: https://www.globenewswire.com/news-release/2013/10/28/584072/10054563/en/Mati-Therapeutics-Inc-Announces-Initiation-of-Phase-II-Study-to-Compare-Latanoprost-Pu.
   Google Scholar
• Development, what differentiates TODDD™ from other sustained delivery technologies in development? 2017-18, amorphex therapeutics LLC [cited 2020 Apr 15]; Available from: https://www.amorphexusa.com/development.
   Google Scholar
• Molokhia SA, Thomas SC, Garff KJ, et al. Anterior eye segment drug delivery systems: current treatments and future challenges. J Ocul Pharmacol Ther. 2013;29(2):92–105. DOI:10.1089/jop.2012.0241
   PubMed Web of Science ®Google Scholar
• Crawford K, Ellis J, Rulander J, et al. Sustained delivery of prostaglandin from drug-containing depots using ocular rings in beagles. Invest Ophthalmol Visual Sci. 2013;54(15):5073–5073.
   Web of Science ®Google Scholar
• Platform technology transforming ocular drug delivery. [cited 2020 3 Mar]; Available from: https://www.liviakis.com/wp-content/uploads/2016/02/Amorphex-Deck-2016.pdf.
   Google Scholar
• Varma DK. Sustained-release drug delivery: closer than you think! Glaucoma Today; 2018. https://glaucomatoday.com/archive/2023
   Google Scholar
• Ocular TherapeutixTM completes end-of-phase 2 review with FDA for OTX-TP (Sustained release travoprost) for glaucoma and ocular hypertension). Apr 27, 2016 [cited Jul 10, 2020]; Available from: https://www.businesswire.com/news/home/20160427006688/en/Ocular-TherapeutixTM-Completes-End-of-Phase-2-Review-FDA.
   Google Scholar
• Punctal plug drug delivery attractive method for managing glaucoma. Nov 11, 2017. [cited Jul 11, 2020]; Available from: https://www.ophthalmologytimes.com/view/punctal-plug-drug-delivery-attractive-method-managing-glaucoma.
   Google Scholar
• Bhattachar SN, Bender DM, Sweetana SA, et al. Discovery formulations: approaches and practices in early preclinical development, in discovering and developing molecules with optimal drug-like properties. Springer; 2015. p. 49–94. DOI:10.1007/978-1-4939-1399-2_2
   Google Scholar
• Inc Q QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery System. 2010 [cited Jul, 10, 2020]; Available from: https://www.globenewswire.com/fr/news-release/2010/03/10/416107/186272/en/QLT-Announces-Phase-II-Clinical-Trial-Results-and-Development-Plans-for-the-Punctal-Plug-Delivery-System.html.
   Google Scholar
• Addo RT, Addo RT. Ocular drug delivery: advances, challenges and applications. Springer: 2016. DOI:10.1007/978-3-319-47691-9
   Google Scholar
• Lavik E, Kuehn M, Kwon Y. Novel drug delivery systems for glaucoma. Eye. 2011;25(5):578–586.
   PubMed Web of Science ®Google Scholar
• Nayak K, Misra M. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother. 2018;107:1564–1582.
   PubMed Web of Science ®Google Scholar
• Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 2001;215(3):143–155.
   PubMed Web of Science ®Google Scholar
• Shirley M. Bimatoprost implant: first approval. Drugs & Aging; 2020.
   Google Scholar
• Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res. 2011;6(4):317. https://link.springer.com/article/10.1007/s40266-020-00769-8
   PubMedGoogle Scholar
• Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension. Jan 07, 2019 [cited Jul 14, 2020]; Available from: https://www.prnewswire.com/news-releases/allergan-announces-positive-3-month-topline-results-from-second-phase-3-study-of-bimatoprost-sr-sustained-release-implant-for-lowering-intraocular-pressure-iop-in-patients-with-open-angle-glaucoma-or-ocular-hypertension-300773602.html.
   Google Scholar
• Lee SS, Burke J, Shen J, et al. Bimatoprost sustained‐release intracameral implant reduces episcleral venous pressure in dogs. Vet Ophthalmol. 2018;21(4):376–381. DOI:10.1111/vop.12522
   PubMed Web of Science ®Google Scholar
• Navratil T, Maynor B, Yerxa B. Improving outcomes in ophthalmology via sustained drug delivery. ONdrugDelivery. 2014;48:10–13.
   Google Scholar
• Williams S, Das S, Hansen J, et al. Fabrication of shape and size specific nanoparticles for ocular drug delivery. Invest Ophthalmol Visual Sci. 2015;56(7):5026–5026.
   Web of Science ®Google Scholar
• Thumann G, Mihov G, Thies J, et al. Slow-release intraocular drug delivery by injectable PEA microfibrils (DSM, NL). Invest Ophthalmol Visual Sci. 2013;54(15):5045–5045.
   Web of Science ®Google Scholar
• Sustained Release Technology. May 3, 2018, [cited Jul 15, 2020; Available from: https://aeriepharma.com/rd/pipeline/drug-delivery/.
   Google Scholar
• Navratil T, Garcia A, Verhoeven RS, et al. Advancing ENV515 (travoprost) intracameral implant into clinical development: nonclinical evaluation of ENV515 in support of first-time-in-human phase 2a clinical study. Invest Ophthalmol Visual Sci. 2015;56(7):5706–5706.
   PubMedGoogle Scholar
• Envisia Therapeutics’ Lead Product Candidate, ENV515 (travoprost XR), Achieves Primary Efficacy Endpoint In Phase 2a Glaucoma Clinical Trial. 2015 [cited Jul, 17, 2020]; Available from: https://www.prnewswire.com/news-releases/envisia-therapeutics-lead-product-candidate-env515-travoprost-xr-achieves-primary-efficacy-endpoint-in-phase-2a-glaucoma-clinical-trial-300154705.htm.
   Google Scholar
• Langh J, Blizzard CD, Driscoll A, et al. Effect of hydrogel persistence on pharmacodynamics and tolerability of OTX-TIC, travoprost intracameral implant in beagles. Invest Ophthalmol Visual Sci. 2020;61(7):1242–1242.
   Web of Science ®Google Scholar
• Blizzard CD, Desai A, Langh J, et al. Pharmacokinetics of OTX-TIC, a sustained release travoprost intracameral implant in rabbits. Invest Ophthalmol Visual Sci. 2019;60(9):3777–3777.
   Web of Science ®Google Scholar
• Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma 2019 [cited Jul, 16, 2020]; Available from: https://www.biospace.com/article/releases/ocular-therapeutix-announces-topline-results-of-ph.
   Google Scholar
• Enabling Site-Specific Drug Delivery. [cited Jun, 19, 2020]; Available from: https://polyactiva.com/platform/#:~:text=The%20polytriazole%20system%20allows%20polymeric%20prodrugs%20to%20be,liner%20thermoplastic%2C%20cross-linked%20hydrogels%20and%20branched%20polymer%20systems.
   Google Scholar
• Adams CM, Papillon JPN. Recent developments for the treatment of glaucoma. In: Cioffi CL, editor. Drug delivery challenges and novel therapeutic approaches for retinal diseases. Cham: Springer International Publishing; 2020. p. 189–256. DOI:10.1007/7355_2019_92
   Google Scholar
• Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma.Full Text View-ClinicalTrials.gov. Jul 27, 2018 [cited 2020 Apr 8]; Available from: https://clinicaltrials.gov/ct2/show/NCT03604328.
   Google Scholar
• Sharif NA, Kirihara T, Iwamura R, et al. A novel non‐prostaglandin EP2‐receptor agonist for glaucoma treatment: omidenepag isopropyl (DE‐117). Faseb J. 2020;34(S1):1–1. DOI:10.1096/fasebj.2020.34.s1.08817
   Google Scholar
• Duggan S. Omidenepag isopropyl ophthalmic solution 0.002%: first global approval. Drugs. 2018;78(18):1925–1929.
   PubMed Web of Science ®Google Scholar
• Our Technology, DurasertTM Technology. [cited 2020 Jul, 7, 2020]; Available from: https://eyepointpharma.com/our-technology/
   Google Scholar
• Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmol. 2014;121(10):1892–1903. e3. DOI:10.1016/j.ophtha.2014.04.019
   PubMed Web of Science ®Google Scholar
• Zhao L, Raval VE, Briggs N, et al. From discovery to scale-up: α-lipoic acid: nicotinamide co-crystals in a continuous oscillatory baffled crystalliser. Cryst Eng Comm. 2014;16(26):5769–5780. DOI:10.1039/C4CE00154K
   Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmol. 2010;117(7):1393–1399. e3. DOI:10.1016/j.ophtha.2009.11.024
   PubMed Web of Science ®Google Scholar
• Wong TT, Novack GD, Natarajan JV, et al. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops. drug delivery and translational research. Drug Deliv Transl Res. 2014;4(4):303–309. DOI:10.1007/s13346-014-0196-9
   PubMed Web of Science ®Google Scholar
• Natarajan JV, Ang M. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomed. 2012;7:123.
   PubMed Web of Science ®Google Scholar
• POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma. [cited Jul, 26, 2020; Available from: https://clinicaltrials.gov/ct2/show/NCT02466399.
   Google Scholar
• SooHoo JR. Glaucoma patient treatment preferences. Ophthalmol. 2016;123(7):1621–1622. DOI:10.1016/j.ophtha.2016.01.018
   PubMed Web of Science ®Google Scholar
• Goldberg DF, Williams R. A phase 2 study evaluating safety and efficacy of the latanoprost punctal plug delivery system (L-PPDS) in subjects with ocular hypertension (OH) or open-angle glaucoma (OAG). Invest Ophthalmol Visual Sci. 2012;53(14):5095–5095.
   PubMedGoogle Scholar
• Seal JR, Robinson MR, Burke J, et al. Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues. J Ocul Pharmacol Ther. 2019;35(1):50–57. DOI:10.1089/jop.2018.0067
   PubMed Web of Science ®Google Scholar
• Parikh NB, Francis JH, Latkany RA. Retention rate of silicone punctal plugs placed by residents in a general clinic setting. Ophth Plastic Recon Surg. 2010;26(6):400–402.
   PubMed Web of Science ®Google Scholar